National Pension Service Has $90.29 Million Stock Position in Becton, Dickinson and Company $BDX

Key Points

• National Pension Service increased its Becton, Dickinson and Company position by 7% in the second quarter, owning 596,647 shares valued at approximately $90.29 million. Institutional investors collectively hold 86.97% of the company.
• BD reported quarterly EPS of $3.23 and revenue of $4.98 billion, exceeding analyst estimates, while revenue rose 5.4% year over year. The company declared a quarterly dividend of $1.05, equivalent to a 2.4% annual yield.
• Insiders sold 8,005 shares worth about $1.42 million over the past 90 days. Analysts maintain a consensus “Hold” rating, with an average price target of $187.67.

National Pension Service boosted its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 596,647 shares of the medical instruments supplier's stock after acquiring an additional 38,982 shares during the quarter. National Pension Service owned 0.22% of Becton, Dickinson and Company worth $90,291,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Larson Financial Group LLC lifted its holdings in Becton, Dickinson and Company by 1.7% in the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier's stock valued at $627,000 after buying an additional 53 shares during the period. Brown Lisle Cummings Inc. raised its holdings in Becton, Dickinson and Company by 9.2% during the second quarter. Brown Lisle Cummings Inc. now owns 644 shares of the medical instruments supplier's stock worth $97,000 after buying an additional 54 shares during the last quarter. Atlantic Union Bankshares Corp raised its stake in shares of Becton, Dickinson and Company by 0.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier's stock worth $1,185,000 after purchasing an additional 57 shares during the last quarter. Elevation Point Wealth Partners LLC lifted its position in shares of Becton, Dickinson and Company by 3.7% during the second quarter. Elevation Point Wealth Partners LLC now owns 1,692 shares of the medical instruments supplier's stock valued at $256,000 after purchasing an additional 60 shares in the last quarter. Finally, Private Harbour Investment Management & Counsel LLC raised its stake in shares of Becton, Dickinson and Company by 1.1% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 5,511 shares of the medical instruments supplier's stock worth $834,000 after purchasing an additional 62 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael Garrison sold 1,100 shares of the business's stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares of the company's stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 4,152 shares of the stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 8,005 shares of company stock worth $1,423,580. Corporate insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $177.85 on Friday. The stock has a market cap of $49.00 billion, a price-to-earnings ratio of 53.57, a price-to-earnings-growth ratio of 12.43 and a beta of 0.21. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The stock has a 50 day moving average price of $172.51 and a 200-day moving average price of $160.65. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm's revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be paid a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company's dividend payout ratio is presently 126.51%.

Wall Street Analyst Weigh In

BDX has been the subject of several analyst reports. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a report on Friday, August 7th. The Goldman Sachs Group lowered their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 27th. Royal Bank Of Canada raised their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research note on Thursday, August 13th. Wells Fargo & Company boosted their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a research report on Friday, August 7th. Finally, Piper Sandler increased their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $187.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.